CERO THERAPEUTICS HOLDINGS, INC. Amortization of Debt Discount (Premium)
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Amortization of Debt Discount (Premium) of $609.88 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-14
- CERO THERAPEUTICS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2026-06-30 was $609.88K.
- CERO THERAPEUTICS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $136.76K.
- CERO THERAPEUTICS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00.
- CERO THERAPEUTICS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month |
|---|---|---|
| 2026-06-30 | $609.88K 10-Q · filed 2026-08-14 | $746.65K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $136.76K 10-Q · filed 2026-05-15 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |